Health Minister Announces Bio‑Surveillance Programme for Transplant Medicines

In a landmark announcement at the sixth National Pharmacovigilance Week, Health and Family Welfare Minister Anupriya Patel gave formal approval to India’s Bio‑Surveillance Programme. The scheme focuses on medicines and biological products used in organ and tissue transplantation, establishing a robust framework for reporting, evaluating and preventing adverse events.

Under the new programme, both donor and recipient sites will be required to log any complications linked to immunosuppressants, biologics or tissue‑derived treatments. Data collected will be processed through the existing ADR‑PVPI 2.0 system, ensuring consistency with the broader pharmacovigilance architecture.

Patel highlighted that India’s rise from the 123rd to the 8th position in the World Health Organization’s patient safety database reflects the country’s growing capacity to generate its own safety evidence, rather than relying solely on external sources.

The Bio‑Surveillance initiative complements ongoing efforts in pharmacovigilance, materiovigilance and device safety, completing a triad of surveillance mechanisms that safeguard drugs, medical devices and transplant procedures.

Industry leaders and clinical researchers praised the move, noting that a unified reporting infrastructure will accelerate the identification of risk patterns and drive evidence‑based regulatory actions.